Scarica l'app Stockscreener
3.65
1.22%
-0.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ESPR Giù?
Forum
Previsione
Frazionamento azionario
Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap UpWhat's Next? - MarketBeat
Is Esperion Therapeutics Inc a good long term investmentGlobal Trade Effects & Free Rapid Wealth Building - earlytimes.in
Esperion Therapeutics (NASDAQ:ESPR) Shares Down 4.8%Time to Sell? - MarketBeat
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
PFE6265887 Bond Coupon Analysis — Rate & Payments - TradingView — Track All Markets
Esperion Therapeutics (NASDAQ:ESPR) Hits New 52-Week HighTime to Buy? - MarketBeat
Is Esperion Therapeutics Inc. stock attractive for long term wealth buildingPortfolio Update Summary & Real-Time Volume Triggers - Улправда
Will Esperion Therapeutics Inc. stock split attract more investorsJuly 2025 Intraday Action & Weekly High Return Stock Forecasts - DonanımHaber
How Esperion Therapeutics Inc. (0ET) stock compares with top peersQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - DonanımHaber
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes - The Manila Times
Esperion's Bempedoic Acid Recognized by ACC as Effective LDL-C Lowering Therapy for Patients with PAD and Diabetes - Quiver Quantitative
Esperion’s Bempedoic Acid Receives Recommendation in 2025 - GlobeNewswire
Take Profit: Will Esperion Therapeutics Inc. stock maintain momentum in 2025 - DonanımHaber
Can Esperion Therapeutics Inc. stock hit record highs againJuly 2025 Macro Moves & AI Powered Market Entry Strategies - Улправда
Esperion Therapeutics Q3 2025 Earnings Preview - MSN
[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity - Stock Titan
Esperion Therapeutics (ESPR) CEO files Form 4 for 48,244-share tax sale - Stock Titan
Esperion Therapeutics (NASDAQ:ESPR) General Counsel Sells $23,917.39 in Stock - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) CFO Benjamin Halladay Sells 7,337 Shares - MarketBeat
Esperion Therapeutics Executives Sell Shares to Satisfy Tax Obligations - TradingView — Track All Markets
CFO Halladay Surrenders 7,337 Of Esperion Therapeutics Inc [ESPR] - TradingView — Track All Markets
Esperion Therapeutics (ESPR) CFO reports 7,337-share sale for tax obligations - Stock Titan
Aug Macro: Will Esperion Therapeutics Inc. (0ET) stock outperform value peers2025 EndofYear Setup & Community Verified Swing Trade Signals - ulpravda.ru
Officer Looker Files To Sell 6,517 Of Esperion Therapeutics Inc [ESPR] - TradingView — Track All Markets
PFE6265887 Bond Analysis — Key Metrics - TradingView — Track All Markets
Investors Purchase High Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR) - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Sets New 12-Month HighShould You Buy? - MarketBeat
Esperion’s Stock Surge: Opportunity Knocks? - StocksToTrade
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sahm
Why The Narrative Around Esperion Therapeutics Is Shifting After Analyst Upgrades And Trial Results - Yahoo Finance
Esperion announces inducement grants under Nasdaq Listing Rule - marketscreener.com
Esperion Grants Stock Options and RSUs to New Chief Commercial Officer and Employees - Quiver Quantitative
Esperion Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Two Seas Capital LP Raises Holdings in Esperion Therapeutics, Inc. $ESPR - MarketBeat
Will Esperion Therapeutics Inc. (0ET) stock enhance shareholder valueEarnings Overview Summary & Smart Money Movement Alerts - Newser
Esperion stock hits fair value target with 77% gain since April 2024 - Investing.com Australia
Esperion Therapeutics, Inc.Common Stock (Nasdaq:ESPR) Stock Quote - Markets Financial Content
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Esperion Therapeutics Inc. (0ET) stock a top dividend aristocrat candidateTrend Reversal & Stepwise Trade Execution Plans - Newser
ESPR SEC FilingsEsperion Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Esperion Therapeutics (NASDAQ:ESPR) Trading 6% HigherHere's What Happened - MarketBeat
Esperion a new overweight at Piper Sandler on CV franchise - MSN
Traders Purchase Large Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR) - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Coverage Initiated at Piper Sandler - MarketBeat
Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug - Stocktwits
Esperion Therapeutics: Soaring Momentum Observed - StocksToTrade
Piper Sandler Initiates Coverage of Esperion Therapeutics (ESPR) with Overweight Recommendation - Nasdaq
Piper Sandler initiates Esperion Therapeutics stock with Overweight rating By Investing.com - Investing.com South Africa
Esperion’s Strategic Moves: What It Means? - StocksToTrade
Esperion Therapeutics Shares Rise After Piper Sandler Initiates Coverage - marketscreener.com
Esperion Stock Grows Amid Promising Japanese Partnership and Q3 Earnings - timothysykes.com
Why Analysts Are Rewriting Esperion’s Story After New Pipeline Results and Global Partnerships - Yahoo Finance
Esperion gains after Piper Sandler initiates with 'overweight' rating - TradingView
2.71%
1.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):